Desvenlafaxine Succinate in Major Depressive Disorder: Effects on Structural and Functional Imaging, Cognition, and Functional Outcomes in Midlife Women and Men.
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Desvenlafaxine (Primary)
- Indications Major depressive disorder
- Focus Pharmacodynamics; Registrational
- 07 Feb 2012 Planned end date changed from 1 Apr 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 03 Jul 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 05 May 2009 New trial record